Antimicrobial Agents and Chemotherapy · 2017 · 43 citations · 27 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceDrug DiscoveryMedical MicrobiologyAntibacterial AgentsAntibacterial PharmacologyAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceTopoisomerase InhibitorsAcinetobacter Baumannii InfectionAcinetobacter Baumannii ResistanceAntibacterial PropertiesFluoroquinolone AntibioticsMultidrug-resistant OrganismsMultidrug-resistant PathogensNovel Antibacterial AgentsTopoisomerase Activity
ABSTRACT The novel bacterial topoisomerase inhibitor class is an investigational type of antibacterial inhibitor of DNA gyrase and topoisomerase IV that does not have cross-resistance with the quinolones. Here, we report the evaluation of the in vitro properties of a new series of this type of small molecule. Exemplar compounds selectively and potently inhibited the catalytic activities of Escherichia coli DNA gyrase and topoisomerase IV but did not block the DNA breakage-reunion step. Compounds showed broad-spectrum inhibitory activity against a wide range of Gram-positive and Gram-negative pathogens, including biodefence microorganisms and Mycobacterium tuberculosis . No cross-resistance with fluoroquinolone-resistant Staphylococcus aureus and E. coli isolates was observed. Measured MIC 90 values were 4 and 8 μg/ml against a panel of contemporary multidrug-resistant isolates of Acinetobacter baumannii and E. coli , respectively. In addition, representative compounds exhibited greater antibacterial potency than the quinolones against obligate anaerobic species. Spontaneous mutation rates were low, with frequencies of resistance typically <10 −8 against E. coli and A. baumannii at concentrations equivalent to 4-fold the MIC. Compound-resistant E. coli mutants that were isolated following serial passage were characterized by whole-genome sequencing and carried a single Arg38Leu amino acid substitution in the GyrA subunit of DNA gyrase. Preliminary in vitro safety data indicate that the series shows a promising therapeutic index and potential for low human ether-a-go-go-related gene (hERG) inhibition (50% inhibitory concentration [IC 50 ], >100 μM). In summary, the compounds' distinct mechanism of action relative to the fluoroquinolones, whole-cell potency, low potential for resistance development, and favorable in vitro safety profile warrant their continued investigation as potential broad-spectrum antibacterial agents.
27
Type IIA topoisomerase inhibition by a new class of antibacterial agents
B.D. Bax, Pan F. Chan, Drake S. Eggleston et al. · Nature · 2010 · 842 citations
Helen W. Boucher, George H. Talbot, Daniel K. Benjamin et al. · Clinical Infectious Diseases · 2013 · 696 citations · Full text
Gregory S. Bisacchi, John I. Manchester · ACS Infectious Diseases · 2014 · 180 citations · Full text